|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry (IHC) was used to determine the presence of WNT5A protein in the sections of formalin-fixed, paraffin-embedded tissue specimens derived from unchanged endome-trial controls (n = 6) and EC tumors (n = 19).
|
31198984 |
2019 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The methylation of WNT5A was statistically significantly correlated to greater tumor size and poor prognosis characteristics and in advanced stage disease with shorter OS.
|
30643192 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Wnt5a overexpression inhibited SMMC-7721 cell proliferation with a significant reduction in S-phase cells and an enrichment of G1-phase cells, a lower colony formation rate, and decreased tumor volumes in the xenograft model compared with those that of control tumors.
|
31436250 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of Wnt5a trap in the tumor, although transient, was greater than that of any other major organs including liver, resulting in a significant reduction of the Wnt5a level in the tumor microenvironment without systematic toxicity.
|
29370526 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Genes associated with tumor microenvironment (CD4, CD14, ADAMTS1, CCL5, CXCL12, CCL19), therapeutic implications (DPYD) and oncogenic signaling (Wnt5A, PTRF) were significantly associated with patient age, histology, tumor status, measurable lesions and metastasis.
|
29061504 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The result illustrated that BBR and knockdown of HNF4α suppressed tumor growth <i>in vivo</i>, and BBR decreased HNF4α, WNT5A and cytoplasmic β-catenin levels, the same effect as HNF4α knockout <i>in vivo</i>.
|
30405404 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
WNT5A, a representative ligand of activating several non-canonical WNT signal pathways, plays significant roles in oncogenesis and tumor inhibition.
|
29345412 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, plasma Wnt5a levels in adrenal vein sampling were helpful in differentiating tumor localization, and preoperative plasma Wnt5a levels predicted the cure of hypertension after adrenalectomy.
|
30085132 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
5-FU-induced tumor suppression (reduced cell viability) was reduced by WNT5A overexpression in hypermethylated HCT116 and SW620 cells and enhanced by WNT5A downregulation in unmethylated LoVo and SW480 cells.
|
28051879 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
For assessing the effects of Wnt5a on tumor growth and metastasis <i>in vivo</i>, A549 cells transfected with sh-Wnt5a were subcutaneously or orthotopically injected into nude mice.
|
29054966 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, high expression levels of the Wnt5a-S mRNA isoform and low expression levels of the Wnt5a-L mRNA isoform were significantly positively correlated with tumor depth of CRC patients.
|
28859077 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our meta-analysis, revealed a statistically significant associations of WNT5A-positivity with lymph node metastasis (p=0.0047), some types of Lauren diffuse subtype GCs (p<0.0001), advanced tumor depth (p<0.0001), and advanced UICC stages (p=0.0461) with no observation of bias or confounding factors.
|
28135710 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using rosiglitazone, we queried the effects of rosiglitazone on Klotho/Wnt5A cross-talk, <i>in vitro</i> and <i>in vivo</i>, and the implications of that for targeted therapy in young versus aged animals.<b>Results:</b> We show that rosiglitazone increases klotho and decreases Wnt5A in tumor cells, reducing the burden of both BRAF inhibitor-sensitive and BRAF inhibitor-resistant tumors in aged, but not young mice.
|
28232477 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To conclude, our data indicate that the WNT5A-mimicking peptide Foxy-5, which has been recently used in a phase 1 clinical trial, is an attractive candidate for complimentary anti-metastatic treatment of prostate cancer patients with tumors exhibiting absent or low WNT5A expression.
|
28886116 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, ROR2 and Wnt5a may act as tumor suppressor genes in the development of PTC; overexpression of ROR2 and Wnt5a in PTC may be important for tumorigenesis and tumor development.
|
29113233 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Wnt5a and Ror2 expression were associated with local invasion and clinical stage, respectively (P < 0.05), and had no significant correlation with age, gender, and tumor size.
|
26608372 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The Wnt5A-ROR2 signaling pathway plays essential roles in the migration and invasion of several types of tumor cell and influences their cell polarity.
|
28536612 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results show that WNT5A signaling regulates 15-PGDH expression, thus uncovering a novel mechanism by which WNT5A acts as a tumor suppressor and suggests that increased 15-PGDH expression could be used as an indicator of a positive response to Foxy-5 in patients treated with this WNT5A agonist.
|
27522468 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This provides a novel mechanism for how Wnt5a exerts tumor suppressive effects and why disruption of Wnt5a signaling enhances mammary tumor growth in vivo.
|
27500936 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Meanwhile, Wnt5a also exhibits a tumor-suppressive function in certain cancers, including breast and colorectal carcinomas.
|
25619716 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-217 targeting Wnt5a in osteosarcoma functions as a potential tumor suppressor.
|
26054690 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Wnt5a may act as a tumor-suppressor gene in HCC, which works through the non-canonical Wnt signaling pathway by binding to the Ror2 and E-cadherin receptor.
|
24696716 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our finding supports that WIF-1 is frequently methylated and that Wnt5a acts as a tumor suppressor gene in CRC.
|
24833087 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The concordance rates between the primary tumor and metastatic site were 76.2% for wnt5a and 79.4% for wnt3a and β-catenin, but VEGFR-2 was expressed in 67.4% of the metastatic sites even when not found in the primary tumor.
|
24564183 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings indicate that Wnt5a might act as tumor suppressor by inhibiting cell proliferation and attenuating EMT in colon cancer cells.
|
24464650 |
2014 |